A Multicenter, Randomized Study of the Safety and Preliminary Efficacy of Low-Dose Nicotine Gel (ATG002) in Patients With Plantar Diabetic Foot Ulcers

The purpose of this study is to evaluate the safety and preliminary efficacy of low dose nicotine gel in patients with chronic diabetic ulcers

Start Date01 Oct 2006

Sponsor / Collaborator

CoMentis, Inc.

100 Clinical Results associated with ATG-002

100 Translational Medicine associated with ATG-002

100 Patents (Medical) associated with ATG-002

Literatures (Medical) associated with ATG-002

01 May 2024·Transplantation and Cellular Therapy

Outcomes of Antithymocyte Globulin-Post-Transplantation Cyclophosphamide-Cyclosporine-Based versus Antithymocyte Globulin-Based Prophylaxis for 10/10 HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Article

Author: Santos Carreira, Abel ; Alfaro-Moya, Tommy ; Kim, Dennis Dong Hwan ; Pasic, Ivan ; Novitzky-Basso, Igor ; Michelis, Fotios V ; Salas, Maria Queralt ; Datt Law, Arjun ; Howard Lipton, Jeffrey ; Mattsson, Jonas ; Gerbitz, Armin ; Viswabandya, Auro ; Lam, Wilson ; Chen, Carol ; Kumar, Rajat ; Atenafu, Eshetu G

In 2015, dual T cell depletion with antithymocyte globulin (ATG) and post-transplantation cyclophosphamide (PTCy) combined with cyclosporine A (CsA) replaced our prior institutional graft-versus-host disease (GVHD) prophylaxis regimen of 4.5 mg/kg ATG, CsA, and mycophenolate mofetil (MMF) (ATG-based) in 10/10 HLA-matched unrelated donor (MUD) peripheral blood allogeneic hematopoietic stem cell transplantation (allo-HCT). The initial ATG dose of 4.5 mg/kg [ATG(4.5)/PTCy] was reduced to 2 mg/kg [ATG(2)/PTCy] in 2018. This study compares the results obtained from 444 adults undergoing MUD allo-HCT at our institution who received ATG(4.5)/PTCy (n = 127) or ATG(2)/PTCy (n = 223) with those who received ATG-based prophylaxis without PTCy (n = 84). The rates of grade II-IV and grade III-IV acute GVHD (aGVHD) at day +100 and moderate/severe chronic GVHD (cGVHD) at 1 year were 35.7%, 21.6%, and 14.7%, respectively, in patients receiving ATG-based prophylaxis without PTCy; 16.5%, 4.9%, and 4.3% in patients receiving ATG(4.5)/PTCy; and 23.3% (P = .004), 8.0% (P < .001), and 14.1% (P =.006) in patients receiving ATG(2)/PTCy. One-year overall survival (OS), nonrelapse mortality (NRM), and GVHD-free relapse-free survival (GRFS) were 69.8%, 25.3%, and 52.0%, respectively, for patients receiving ATG-based prophylaxis without PTCy; 82.7%, 17.3%, and 59.8% for patients receiving ATG(4.5)/PTCy; and 78.3% (P = .446), 14.7% (P = 101), and 56.2% (P = .448) for patients receiving ATG(2)/PTCy. On univariate analyses, the use of ATG(2)/PTCy was associated with a lower risk of NRM (hazard ratio, .54; P = .023) compared with the use of ATG-based prophylaxis without PTCy. ATG(2)/PTCy prophylaxis effectively prevents GVHD and is associated with comparable relapse risk, OS, and GRFS as seen with ATG(4.5)/PTCy and ATG-based prophylaxis without PTCy.

16 Aug 2018·BloodQ1 · MEDICINE

Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: a nationwide phase 2 study

Q1 · MEDICINE

Article

Author: Rialland, Fanny ; Rorlich, Pierre S. ; Chevret, Sylvie ; Gluckman, Eliane ; Galambrun, Claire ; Sirvent, Anne ; Paillard, Catherine ; Forcade, Edouard ; Sicre de Fontbrune, Flore ; Dalle, Jean-Hugues ; Mohty, Mohamad ; Ruggeri, Annalisa ; Jubert, Charlotte ; Salmon, Alexandra ; Fürst, Sabine ; Larghero, Jerome ; Bay, Jacques-Olivier ; Rubio, Marie Therese ; Peffault de Latour, Regis ; Bruno, Benedicte ; Socié, Gerard ; Cornillon, Jérôme ; Gandemer, Virginie

Key PointsCBT after FLU-CY-ATG-2-Gy TBI with at least 4 × 107 frozen NCs per kilogram leads to satisfactory OS in refractory SAA. CBT is a valuable curative option in young patients with refractory idiopathic SAA and no available matched unrelated donors.

100 Deals associated with ATG-002

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetic foot ulcer	Phase 2	US	CoMentis, Inc.	01 Oct 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

ATG-002

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation